Mark Jeffrey DeLong, Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 1,780 shares at $22.19 ($39K) on 2026-01-13, disclosed to the SEC on 2026-01-15.
Seasonal sale ($39k) by Chief Business & Strat Officer — this insider has traded APLS in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2026-01-21 | $26K | — | Filing → |
| APLS | SELL | 2025-02-12 | $10K | — | Filing → |
| APLS | SELL | 2025-01-30 | $11K | — | Filing → |